These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

969 related items for PubMed ID: 10502236

  • 1. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM.
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [Abstract] [Full Text] [Related]

  • 2. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G.
    J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
    [Abstract] [Full Text] [Related]

  • 3. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.
    Pang JT, Fort S, Della Siega A, Cohen EA.
    J Card Surg; 2002 Apr; 17(5):425-31. PubMed ID: 12630543
    [Abstract] [Full Text] [Related]

  • 4. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
    [Abstract] [Full Text] [Related]

  • 5. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
    Juran NB.
    Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
    [Abstract] [Full Text] [Related]

  • 6. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
    PRICE Investigators.
    Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437
    [Abstract] [Full Text] [Related]

  • 7. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 8. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
    Tcheng JE.
    Am J Cardiol; 1996 Aug 14; 78(3A):35-40. PubMed ID: 8751845
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE, Gupta R, Rajendran S, Luu J, French JK, Juergens CP.
    Cardiovasc Ther; 2016 Oct 14; 34(5):330-6. PubMed ID: 27327862
    [Abstract] [Full Text] [Related]

  • 10. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P, NICE-3 Investigators.
    Am Heart J; 2003 Oct 14; 146(4):628-34. PubMed ID: 14564315
    [Abstract] [Full Text] [Related]

  • 11. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators.
    JAMA; 2003 Feb 19; 289(7):853-63. PubMed ID: 12588269
    [Abstract] [Full Text] [Related]

  • 12. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
    Kimmelstiel C, Phang R, Rehman A, Rand W, Miele R, Rhofiry J, MacIsaac DA, Gouveia W, Denier D, Becker RC.
    J Thromb Thrombolysis; 2001 May 19; 11(3):203-9. PubMed ID: 11577258
    [Abstract] [Full Text] [Related]

  • 13. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM, Califf RM, Topol EJ.
    J Am Coll Cardiol; 2000 Apr 19; 35(5):1103-15. PubMed ID: 10758948
    [Abstract] [Full Text] [Related]

  • 14. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
    Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I.
    Cochrane Database Syst Rev; 2014 Mar 08; (3):CD005208. PubMed ID: 24609741
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL, Topol EJ.
    JAMA; 2000 Sep 27; 284(12):1549-58. PubMed ID: 11000650
    [Abstract] [Full Text] [Related]

  • 17. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
    Young JJ, Kereiakes DJ.
    J Invasive Cardiol; 2002 Jul 27; 14(7):404-10. PubMed ID: 12082194
    [Abstract] [Full Text] [Related]

  • 18. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E, Akkerhuis KM, Théroux P, Califf RM, Topol EJ, Simoons ML.
    Circulation; 1999 Nov 16; 100(20):2045-8. PubMed ID: 10562258
    [Abstract] [Full Text] [Related]

  • 19. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors.
    Blankenship JC.
    Am Heart J; 1999 Oct 16; 138(4 Pt 2):287-96. PubMed ID: 10502234
    [Abstract] [Full Text] [Related]

  • 20. Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.
    Anderson JR, Riding D.
    Cardiol Rev; 2008 Oct 16; 16(4):213-8. PubMed ID: 18562812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.